Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2011

Open Access 01-06-2011 | Research article

Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity

Authors: Qian Wu, Qingrui Yang, Elaine Lourenco, Hongsheng Sun, Yuanchao Zhang

Published in: Arthritis Research & Therapy | Issue 3/2011

Login to get access

Abstract

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organ systems. Previous studies have suggested that interferon-lambda 1 (IFN-λ1), a type III interferon, plays an immunomodulatory role. In this study we investigated its role in SLE, including its correlation with disease activity, organ disorder and production of chemokines.

Methods

We determined levels of IFN-λ1 mRNA in peripheral blood mononuclear cells (PBMC) and serum protein levels in patients with SLE using real-time polymerase chain reaction (real-time PCR) and enzyme-linked immunoassay (ELISA). Further, we detected the concentration of IFN-inducible protein-10 (IP-10), monokine induced by IFN-γ (MIG) and interleukin-8 (IL-8) secreted by PBMC under the stimulation of IFN-λ1 using ELISA.

Results

IFN-λ1 mRNA and serum protein levels were higher in patients with SLE compared with healthy controls. Patients with active disease showed higher IFN-λ1 mRNA and serum protein levels compared with those with inactive disease as well. Serum IFN-λ1 levels were positively correlated with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), anti-dsDNA antibody, C-reactive protein (CRP) and negatively correlated with complement 3. Serum IFN-λ1 levels were higher in SLE patients with renal involvement and arthritis compared with patients without the above-mentioned manifestations. IFN-λ1 with different concentrations displayed different effects on the secretion of the chemokines IP-10, MIG and IL-8.

Conclusions

These findings indicate that IFN-λ1 is probably involved in the renal disorder and arthritis progression of SLE and associated with disease activity. Moreover, it probably plays an important role in the pathogenesis of SLE by stimulating secretion of the chemokines IP-10, MIG and IL-8. Thus, IFN-λ1 may provide a novel research target for the pathogenesis and therapy of SLE.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wong CK, Ho CY, Li EK, Lam CW: Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus. 2000, 9: 589-593.CrossRef Wong CK, Ho CY, Li EK, Lam CW: Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus. 2000, 9: 589-593.CrossRef
2.
go back to reference Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T: Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem. 2007, 282: 7576-7581.CrossRef Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T: Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem. 2007, 282: 7576-7581.CrossRef
3.
go back to reference Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC: Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005, 64: 1692-1697.CrossRef Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC: Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005, 64: 1692-1697.CrossRef
4.
go back to reference Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK, Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC: High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007, 8: 492-502.CrossRef Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK, Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC: High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007, 8: 492-502.CrossRef
5.
go back to reference Csiszar A, Nagy G, Gergely P, Pozsonyi T, Pocsik E: Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 2000, 122: 464-470.CrossRef Csiszar A, Nagy G, Gergely P, Pozsonyi T, Pocsik E: Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 2000, 122: 464-470.CrossRef
6.
go back to reference Chan RW, Tam LS, Li EK, Lai FM, Chow KM, Lai KB, Li PK, Szeto CC: Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 2003, 48: 1326-1331.CrossRef Chan RW, Tam LS, Li EK, Lai FM, Chow KM, Lai KB, Li PK, Szeto CC: Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 2003, 48: 1326-1331.CrossRef
7.
go back to reference Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003, 4: 63-68.CrossRef Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003, 4: 63-68.CrossRef
8.
go back to reference Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC: Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem. 2004, 279: 32269-32274.CrossRef Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC: Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem. 2004, 279: 32269-32274.CrossRef
9.
go back to reference Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I: IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol. 2007, 179: 3434-3442.CrossRef Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I: IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol. 2007, 179: 3434-3442.CrossRef
10.
go back to reference Commins S, Steinke JW, Borish L: The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol. 2008, 121: 1108-1111.CrossRef Commins S, Steinke JW, Borish L: The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol. 2008, 121: 1108-1111.CrossRef
11.
go back to reference Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM: IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther. 2008, 7: 1109-1115.CrossRef Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM: IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther. 2008, 7: 1109-1115.CrossRef
12.
go back to reference Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Göke B, Dambacher J: IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol. 2005, 289: G960-968.CrossRef Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Göke B, Dambacher J: IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol. 2005, 289: G960-968.CrossRef
13.
go back to reference Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM: Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006, 131: 1887-1898.CrossRef Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM: Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006, 131: 1887-1898.CrossRef
14.
go back to reference Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S: Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res. 2007, 126: 245-249.CrossRef Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S: Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res. 2007, 126: 245-249.CrossRef
15.
go back to reference Hou W, Wang X, Ye L, Zhou L, Yang ZQ, Riedel E, Ho WZ: Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol. 2009, 83: 3834-3842.CrossRef Hou W, Wang X, Ye L, Zhou L, Yang ZQ, Riedel E, Ho WZ: Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol. 2009, 83: 3834-3842.CrossRef
16.
go back to reference Mennechet FJ, Uze G: Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood. 2006, 107: 4417-4423.CrossRef Mennechet FJ, Uze G: Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood. 2006, 107: 4417-4423.CrossRef
17.
go back to reference Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, Gallagher G: Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun. 2007, 8: 254-261.CrossRef Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, Gallagher G: Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun. 2007, 8: 254-261.CrossRef
18.
go back to reference Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, Gallagher G: Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology. 2008, 125: 492-502.CrossRef Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, Gallagher G: Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology. 2008, 125: 492-502.CrossRef
19.
go back to reference Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G: Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun. 2007, 8: 13-20.CrossRef Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G: Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun. 2007, 8: 13-20.CrossRef
20.
go back to reference Sallusto F, Lanzavecchia A: Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev. 2000, 177: 134-140.CrossRef Sallusto F, Lanzavecchia A: Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev. 2000, 177: 134-140.CrossRef
21.
go back to reference Premack BA, Schall TJ: Chemokine receptors: gateways to inflammation and infection. Nat Med. 1996, 2: 1174-1178.CrossRef Premack BA, Schall TJ: Chemokine receptors: gateways to inflammation and infection. Nat Med. 1996, 2: 1174-1178.CrossRef
22.
go back to reference Sallusto F: The role of chemokines and chemokine receptors in T cell priming and Th1/Th2-mediated responses. Haematologica. 1999, 84 (Suppl EHA-4): 28-31. Sallusto F: The role of chemokines and chemokine receptors in T cell priming and Th1/Th2-mediated responses. Haematologica. 1999, 84 (Suppl EHA-4): 28-31.
23.
go back to reference Rossi D, Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol. 2000, 18: 217-242.CrossRef Rossi D, Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol. 2000, 18: 217-242.CrossRef
24.
go back to reference Neville LF, Mathiak G, Bagasra O: The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev. 1997, 8: 207-219.CrossRef Neville LF, Mathiak G, Bagasra O: The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev. 1997, 8: 207-219.CrossRef
25.
go back to reference Luster AD, Unkeless JC, Ravetch JV: Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature. 1985, 315: 672-676.CrossRef Luster AD, Unkeless JC, Ravetch JV: Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature. 1985, 315: 672-676.CrossRef
26.
go back to reference Padovan E, Spagnoli GC, Ferrantini M, Heberer M: IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol. 2002, 71: 669-676. Padovan E, Spagnoli GC, Ferrantini M, Heberer M: IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol. 2002, 71: 669-676.
27.
go back to reference Wada T, Yokoyama H, Tomosugi N, Hisada Y, Ohta S, Naito T, Kobayashi K, Mukaida N, Matsushima K: Detection of urinary interleukin-8 in glomerular diseases. Kidney Int. 1994, 46: 455-460.CrossRef Wada T, Yokoyama H, Tomosugi N, Hisada Y, Ohta S, Naito T, Kobayashi K, Mukaida N, Matsushima K: Detection of urinary interleukin-8 in glomerular diseases. Kidney Int. 1994, 46: 455-460.CrossRef
28.
go back to reference Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, Espe KJ, Li W, Patel DD, Gregersen PK, Behrens TW: Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006, 3: e491-CrossRef Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, Espe KJ, Li W, Patel DD, Gregersen PK, Behrens TW: Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006, 3: e491-CrossRef
29.
go back to reference Lit LC, Wong CK, Tam LS, Li EK, Lam CW: Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis. 2006, 65: 209-215.CrossRef Lit LC, Wong CK, Tam LS, Li EK, Lam CW: Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis. 2006, 65: 209-215.CrossRef
30.
go back to reference Narumi S, Takeuchi T, Kobayashi Y, Konishi K: Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine. 2000, 12: 1561-1565.CrossRef Narumi S, Takeuchi T, Kobayashi Y, Konishi K: Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine. 2000, 12: 1561-1565.CrossRef
31.
go back to reference Vila LM, Molina MJ, Mayor AM, Cruz JJ, Rios-Olivares E, Rios Z: Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin Rheumatol. 2007, 26: 718-722.CrossRef Vila LM, Molina MJ, Mayor AM, Cruz JJ, Rios-Olivares E, Rios Z: Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin Rheumatol. 2007, 26: 718-722.CrossRef
32.
go back to reference Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, Takahashi Y, Sasaki T, Furuichi K, Segawa C, Hisada Y, Ohta S, Takasawa K, Kobayashi K, Matsushima K: Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int. 1996, 49: 761-767.CrossRef Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, Takahashi Y, Sasaki T, Furuichi K, Segawa C, Hisada Y, Ohta S, Takasawa K, Kobayashi K, Matsushima K: Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int. 1996, 49: 761-767.CrossRef
33.
go back to reference Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35: 630-640.CrossRef Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35: 630-640.CrossRef
34.
go back to reference Croker JA, Kimberly RP: SLE: challenges and candidates in human disease. Trends Immunol. 2005, 26: 580-586.CrossRef Croker JA, Kimberly RP: SLE: challenges and candidates in human disease. Trends Immunol. 2005, 26: 580-586.CrossRef
35.
go back to reference Balow JE: Clinical presentation and monitoring of lupus nephritis. Lupus. 2005, 14: 25-30.CrossRef Balow JE: Clinical presentation and monitoring of lupus nephritis. Lupus. 2005, 14: 25-30.CrossRef
36.
go back to reference Pekarek V, Srinivas S, Eskdale J, Gallagher G: Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. Genes Immun. 2007, 8: 177-180.CrossRef Pekarek V, Srinivas S, Eskdale J, Gallagher G: Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. Genes Immun. 2007, 8: 177-180.CrossRef
37.
go back to reference de Carvalho JF, Hanaoka B, Szyper-Kravitz M, Shoenfeld Y: C-Reactive protein and its implications in systemic lupus erythematosus. Acta Reumatol Port. 2007, 32: 317-322. de Carvalho JF, Hanaoka B, Szyper-Kravitz M, Shoenfeld Y: C-Reactive protein and its implications in systemic lupus erythematosus. Acta Reumatol Port. 2007, 32: 317-322.
38.
go back to reference Zein N, Ganuza C, Kushner I: Significance of serum C-reactive protein elevation in patients with systemic lupus erythematosus. Arthritis Rheum. 1979, 22: 7-12.CrossRef Zein N, Ganuza C, Kushner I: Significance of serum C-reactive protein elevation in patients with systemic lupus erythematosus. Arthritis Rheum. 1979, 22: 7-12.CrossRef
39.
go back to reference ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG: C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol. 1990, 17: 1642-1648. ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG: C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol. 1990, 17: 1642-1648.
40.
go back to reference Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED: Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008, 152: 550-556.CrossRef Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED: Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008, 152: 550-556.CrossRef
41.
go back to reference Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A, Davila-Maldonado L, Atisha-Fregoso Y, Llorente L, Sanchez-Guerrero J: Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007, 56: 1242-1250.CrossRef Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A, Davila-Maldonado L, Atisha-Fregoso Y, Llorente L, Sanchez-Guerrero J: Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007, 56: 1242-1250.CrossRef
42.
go back to reference Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, Bao C: Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther. 2008, 10: R112-CrossRef Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, Bao C: Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther. 2008, 10: R112-CrossRef
43.
go back to reference Ka SM, Cheng CW, Shui HA, Wu WM, Chang DM, Lin YC, Chen A: Mesangial cells of lupus-prone mice are sensitive to chemokine production. Arthritis Res Ther. 2007, 9: R67-CrossRef Ka SM, Cheng CW, Shui HA, Wu WM, Chang DM, Lin YC, Chen A: Mesangial cells of lupus-prone mice are sensitive to chemokine production. Arthritis Res Ther. 2007, 9: R67-CrossRef
44.
go back to reference Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de Lema G, Strutz F, Bauer S, Rutz M, Wagner H, Gröne HJ, Schlöndorff D: Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J. 2004, 18: 534-536. Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de Lema G, Strutz F, Bauer S, Rutz M, Wagner H, Gröne HJ, Schlöndorff D: Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J. 2004, 18: 534-536.
45.
go back to reference Pawar RD, Patole PS, Zecher D, Segerer S, Kretzler M, Schlondorff D, Anders HJ: Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol. 2006, 17: 141-149.CrossRef Pawar RD, Patole PS, Zecher D, Segerer S, Kretzler M, Schlondorff D, Anders HJ: Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol. 2006, 17: 141-149.CrossRef
46.
go back to reference Pawar RD, Castrezana-Lopez L, Allam R, Kulkarni OP, Segerer S, Radomska E, Meyer TN, Schwesinger CM, Akis N, Grone HJ, Anders HJ: Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll-like receptor 2 at the glomerular filtration barrier. Immunology. 2009, 128: e206-221.CrossRef Pawar RD, Castrezana-Lopez L, Allam R, Kulkarni OP, Segerer S, Radomska E, Meyer TN, Schwesinger CM, Akis N, Grone HJ, Anders HJ: Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll-like receptor 2 at the glomerular filtration barrier. Immunology. 2009, 128: e206-221.CrossRef
47.
go back to reference Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK: High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007, 8: 492-502.CrossRef Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK: High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007, 8: 492-502.CrossRef
Metadata
Title
Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity
Authors
Qian Wu
Qingrui Yang
Elaine Lourenco
Hongsheng Sun
Yuanchao Zhang
Publication date
01-06-2011
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2011
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3363

Other articles of this Issue 3/2011

Arthritis Research & Therapy 3/2011 Go to the issue